Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | BAX | Q07812 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PNLIP | P16233 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10702237 | 0.85 | LTA4H (0.52) | CAMK2ALTA4HNR1H2BAXCYP1A2 | |
| SCHEMBL8568945 | 0.85 | MEN1 (0.46) | HSD17B10CYP1A2CYP2C9CYP2C19PNLIP | |
| SCHEMBL21633625 | 0.82 | CAMK2A (0.59) | CAMK2ALTA4HNR1H2BAXHSD17B10 | |
| SCHEMBL1028660 | 0.81 | ESR1 (0.44) | CAMK2AHSD17B10 | |
| SCHEMBL18179765 | 0.81 | HSP90AA1 (0.47) | CAMK2AHSD17B10CYP3A4TTRTSHR | |
| SCHEMBL811114 | 0.80 | CYP1A2 (0.61) | LTA4HCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL225442 | 0.80 | CAMK2A (0.57) | CAMK2ALTA4HNR1H2BAXHSD17B10 | |
| SCHEMBL3793518 | 0.80 | LTA4H (0.50) | LTA4HNR1H2BAXCYP1A2CYP3A4 | |
| SCHEMBL10937945 | 0.79 | CYP1A2 (0.53) | LTA4HCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Diphenylether SCHEMBL28106818 | 0.78 | LTA4H (0.53) | CAMK2ALTA4HNR1H2BAXHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| EP-1957493-B1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | ORGANON NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| EP-1957493-B1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | ORGANON NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| EP-1957493-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-08-20 | — | — | EP | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | CAMK2A 4784/4885LTA4H 2866/4885NR1H2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.